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Abstract C-Aminobutyric acid B (GABAB) receptors are
heterodimers composed of two subunits GABAB(1) and
GABAB(2), the former existing in two isoforms GABAB(1a)
and GABAB(1b). The contributions of individual receptor
subunits and isoforms to GABAB auto- and heteroreceptor
functions were investigated, using release experiments in
cortical slice preparations from corresponding knockout
mice. Presynaptic GABAB autoreceptors are located on
GABAergic terminals and inhibit GABA release, whereas
presynaptic GABAB heteroreceptors control the release of
other neurotransmitters (e.g. glutamate). Neither baclofen
nor the selective antagonist CGP55845 at maximally active
concentrations affected [3H]GABA release in slices from
GABAB(1)-/- mice. The amount of [
3H]GABA released
per pulse was unaffected by the stimulation frequency in
slices from GABAB(1)-/- and GABAB(2)-/- demonstrat-
ing a loss of GABAB autoreceptor function in these knockout
animals. The GABAB receptor agonist baclofen was inef-
fective in modulating glutamate release in cortical slices
from GABAB(2)-/- mice, showing that heteroreceptor
function was abolished as well. Next we investigated
knockout mice for the two predominant GABAB(1) isoforms
expressed in brain, GABAB(1a) and GABAB(1b). In cortical,
hippocampal and striatal slices from both GABAB(1a)-/-
and GABAB(1b)-/- mice, the frequency dependence of
[3H]GABA released per pulse was maintained, suggesting
that both isoforms participate or can substitute for each other
in GABAB autoreceptor function. By contrast, the efficacy of
baclofen to inhibit glutamate release was substantially
reduced in GABAB(1a)-/-, but essentially unaltered in
GABAB(1b)-/- mice. Our data suggest that functional
GABAB heteroreceptors regulating glutamate release are
predominantly, but not exclusively composed of GABAB(1a)
and GABAB(2) subunits.
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Abbreviations
AOAA Aminooxyacetic acid
GDH Glutamate dehydrogenase
Ko Knockout
L-trans-PDC L-trans-pyrrolidine-2,4-dicarboxylic acid
Wt Wildtype
Introduction
GABAB receptors comprise the metabotropic, G protein-
coupled receptor system for GABA and modulate inhibitory
and excitatory neurotransmission. Activation of presynaptic
GABAB receptors, via inhibition of Ca
2+ channels, inhibits
the release of several neurotransmitters and neuropeptides.
Presynaptic GABAB autoreceptors are located on GABA-
ergic terminals and inhibit GABA release, whereas
presynaptic GABAB heteroreceptors control the release of
other neurotransmitters (e.g. glutamate). Postsynaptic
GABAB receptors activate inwardly rectifying potassium
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channels (GIRKs) and induce the slow, long-lasting com-
ponent of inhibitory postsynaptic potentials (IPSPs), the fast
component of which is mediated through GABAA recep-
tors. Based on the effectiveness of some GABAB receptor
ligands in preferentially modulating the release of one
versus another neurotransmitter, the existence of different
auto- and heteroreceptor subtypes has been proposed
(Bonanno and Raiteri 1993; Cunningham and Enna 1996),
although this is controversial (Waldmeier et al. 1994).
Molecular cloning and pharmacological characterization
has revealed that native GABAB receptors are heterodimers
composed of two subunits, GABAB(1) (GB1) and
GABAB(2) (GB2; reviewed in Bettler et al. 2004). GABAB
receptors are exceptional among G protein coupled recep-
tor heterodimers in that only one subunit, GB1, contains the
ligand binding domain whereas effector coupling is
entirely mediated through the second subunit, GB2.
Genetic inactivation of either the GB1 or the GB2 subunits
abolishes physiological GABAB receptor responses
(GB1-/- and GB2-/- mice; Prosser et al. 2001; Schuler
et al. 2001; Que´va et al. 2003; Gassmann et al. 2004;
Thuault et al. 2004). The lack of physiological pre- and
postsynaptic GABAB receptor functions in respective
knockout (ko) mice demonstrates that GB1 and GB2 are
essential subunits of all brain GABAB receptors (Prosser
et al. 2001; Schuler et al. 2001; Gassmann et al. 2004).
In the brain two predominant, differentially expressed
isoforms are transcribed from the Gabbr1 gene, GABAB(1a)
(GB1a) and GABAB(1b) (GB1b), which are conserved in
different species including humans (Kaupmann et al. 1997;
Bischoff et al. 1999; Fritschy et al. 1999). Both isoforms
heterodimerize with GB2 to form functional receptors.
The GB1a isoform differs from GB1b by the presence of
a pair of ‘‘sushi repeats’’ at the very N terminal protein
sequence (Hawrot et al. 1998). Using established ligands
the pharmacological profiles of both isoforms are however
indistinguishable (Kaupmann et al. 1997; Kaupmann et al.
1998a, b). Sushi repeats were originally identified in pro-
teins of the complement system and are likely involved in
protein–protein interactions (Lehtinen et al. 2004). In the
rat brain GB1a is the prevalent isoform present at birth
whereas in adult brain tissue GB1b is more abundant
(Malitschek et al. 1998). Transcription of the two isoforms
is regulated by different promoters (Steiger et al. 2004).
Additional isoforms (splice variants) transcribed from the
Gabbr1 gene have been described, however their physio-
logical significance is unclear to date (reviewed in Bettler
et al. 2004).
The goal of the present study was to assess the contri-
butions of individual GABAB receptor isoforms and
subtypes to GABAB autoreceptor and heteroreceptor
functions, using release studies in respective ko mice.
Using brain slice preparations from the recently generated
GB1a and GB1b isoform selective ko mice (Vigot et al.
2006) we measured GABA and glutamate release in
comparison with previously characterized GB1 and GB2
subunit ko mice (Schuler et al. 2001; Gassmann et al.
2004). Our data suggest that the GB1a isoform is mainly,
although not exclusively, involved in heteroreceptor func-
tion regulating glutamate release, whereas both GB1a and
GB1b contribute to autoreceptor function.
Materials and methods
Chemicals
The GABAB antagonist CGP55845 ([3-[[1-(S)-(3,4-
dichlorophenyl)-ethyl]-amino]-2-(S)-hydroxypropyl]-phe-
nylmethylphosphinic acid), the agonist R(–)-baclofen
(p-chlorophenyl-GABA) and the GABA uptake inhibitor
SK&F 89976 (1-(4,4-diphenyl-3-butenyl)-3-piperidine
carboxylic acid) have been synthesized at Novartis. The
GABA transaminase inhibitor, aminooxyacetic acid
(AOAA), and the glutamate uptake inhibitor, L-trans-pyr-
rolidine-2,4-dicarboxylic acid (L-trans-PDC), were obtained
from FLUKA AG (Buchs, Switzerland) and Tocris (Bristol,
UK), respectively. Luciferase (from Photobacterium fisc-
heri, E.C. 1.14.14.3) and NAD(P)H:FMN oxidoreductase
(E.C. 1.6.8.1) were from Roche Diagnostics (Mannheim,
Germany). FMN, NAD, glutamate dehydrogenase (E.C.
1.4.1.3, GDH) and decanal were purchased from Sigma
Aldrich (Buchs, Switzerland), and ADP was from ICN
Biomedicals Inc. (Aurora, OH, USA).
GABAB receptor knockout mice
Ko mice of the different GABAB receptor subunits and
isoforms were generated in the Balb/c inbred strain using a
newly established Balb/c embryonic stem (ES) cell line.
The generation of GB1 and GB2 subunit ko mice
(GB1-/- and GB2-/-) has been described (Schuler et al.
2001; Gassmann et al. 2004). To generate GB1 isoform
selective ko mice (GB1a-/- and GB1b-/-) the respec-
tive start codons of GB1a and GB1b isoforms (Steiger et al.
2004) were converted into stop codons (Vigot et al. 2006).
Release experiments
In each experiment in which the electrically stimulated
release of [3H]GABA or endogenous glutamate was
measured, usually the slices obtained from two or more
mice per genotype were pooled and distributed into the
number of superfusion chambers indicated in the figure
legends (depending on the number of different conditions,
the superfusion apparatus containing 12 chambers). The
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data from the number of experiments given in the figure
legends were pooled for statistical analysis to give a total
of N data points, each data point reflecting a sample
obtained from one superfusion chamber.
Release of [3H]GABA
Electrically stimulated release of [3H]GABA from pre-
loaded mouse brain slices was measured as previously
described for slices from rat brain (Baumann et al. 1990).
Briefly, cross-chopped slices (1,000 9 350 9 350 lm)
were incubated for 5 min with 100 nM [2,3-3H(N)] GABA
(1.25 TBq/mmol, Perkin-Elmer Lifesciences, Boston, MA,
USA) in physiological buffer (composition in mM: NaCl,
118; KCl, 4.8; CaCl2, 2.6; MgSO4, 1.2; KH2PO4, 1.2; (+)-
glucose, 10; NaHCO3, 25; AOAA as an inhibitor of GABA
transaminase, 0.05). 25 ll of slice suspension (&1 mg
protein) were transferred to stimulation chambers and su-
perfused at 0.4 ml/min with physiological buffer gassed
with 5% CO2 in O2, containing 10 lM of the GABA
uptake inhibitor, SK&F 89976. Fractions of 6 min were
collected, beginning 50 min after starting the superfusion.
Radioactivity in the fractions and the slices [collected at
the end of the experiments and solubilized in Soluene 350
(Packard, Meriden, CT, USA)] was counted after addition
of Irgasafe Plus scintillator (Zinsser Analytics, Maiden-
head, UK). Data are means of the stimulated fractional
release ± SEM.
For the comparison of the effect of the GABAB
antagonist, CGP55845, on [3H]GABA release from cor-
tical slices of wildtype (wt) and GB1-/- mice, four
groups of three slice preparations (wt control;
wt + 1 lM CGP55845; GB1-/- control; GB1-/-
+ 1 lM CGP55845) were stimulated three times (S1–S3):
at 2 Hz for 2 min (240 monophasic pulses, 2 ms,
25 mA) during fraction 3, and at 2 Hz for 0.5 min (60
pulses) during fractions 9 and 15; 17 fractions were
collected in total. The compound was added between S2
and S3, in fraction 12. Two identical experiments were
carried out and the results pooled. A similar procedure
was used for assessing the effect of the GABAB agonist,
R(–)-baclofen (10 lM), except that S2 and S3 were at
0.125 Hz (8 min, 60 pulses).
In the experiments in which the dependence of
[3H]GABA release on the stimulation frequency was
assessed in cortical slices, six chambers each containing
slice preparations from wt and ko mice (for gender and age
see figure legends) were stimulated five times (S1–S5;
0.125 Hz for 8 min, during fractions 3 and 4, 0.25 Hz for
4 min (fraction 7), 0.5 Hz for 2 min (fraction 10), 1 Hz for
1 min (fraction 13), and 2 Hz for 30 s (fraction 16),
delivering a constant number of 60 monophasic pulses
(2 ms, 25 mA) at each frequency. A total of 18 fractions
were collected. Each experiment was then repeated, in-
versing the frequency sequence (i.e. beginning with 2 Hz,
ending with 0.125 Hz). The frequency dependence exper-
iments with striatal and hippocampal slices from wt,
GB1a-/- and GB1b-/- mice were only done with
increasing frequencies, because no difference between the
two procedures had been seen in the previous experiments.
Data analysis The significancies of the effects of bac-
lofen and CGP55845 on GABA release (Fig. 1), as well as
those of the differences in GABA release levels between wt
and ko mice (Figs. 2, 3) were assessed by Student’s t test.
On the other hand, the significance of the dependence of
GABA release on the stimulation frequency was calculated
by one-way analysis of variance (ANOVA) followed by
Dunnett’s test, using the values obtained at the lowest
stimulation frequency (0.125 Hz) as the control group.
GraphPad Prism software was used for these calculations.
Release of endogenous glutamate
Mouse cortical slices were prepared as above and super-
fused at 0.4 ml/min with physiological buffer as described
above for [3H]GABA release experiments, but containing
100 lM of the glutamate uptake inhibitor L-trans-PDC
instead of SK&F 89976, as previously described (Wald-
meier et al. 1993b). Collection of twelve 6 min fractions
was begun 50 min after starting the superfusion. Four
groups of slice preparations pooled from at least two ani-
mals each (wt control; wt + R(–)-baclofen 10 lM; ko
control; ko + R(–)-baclofen 10 lM) were electrically
stimulated (1 Hz for 4 min, 2 ms, 25 mA) twice, during
fractions 3 and 10; R(–)-baclofen was added before S2, in
fraction 6.
The glutamate content of the superfusate fractions from
release experiments was determined with a bioluminescence
assay, as described by Fosse et al. (1987). The principle of
the assay is based on an enzymatic cascade, in which the
NADH generated by glutamate dehydrogenase is reoxidized
by NADH:FMN oxidoreductase, the reduced FMNH then
being accepted as a co-factor in the oxidation of a long-chain
aldehyde (decanal) by a light-producing bacterial luciferase.
The measurements were performed in opaque, white 96 well
microtiter plates on a WALLAC Micro Beta 1450 Jet
instrument. To sample or standard solutions (25 ll), 45 ll
of a luminescence reaction mixture (25 mM potassium
phosphate buffer pH 7.0, 100 lM dithiothreitol, 5 lg/ml
luciferase, 200 mU/ml NAD(P)H:FMN oxidoreductase,
2.5 lM FMN, 2 mM NAD, 250 lM ADP, 16% glycerol,
44 U/ml GDH, 20 lM decanal) were injected using a
six channel—injector module. After allowing an initial
peak occurring upon reagent mixing to decay for 12 s, the
light production was measured during 45 s, at room
temperature.
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Data analysis The light produced in the luminometric
assay was converted into the corresponding quantities of
glutamate with the aid of calibration curves obtained
with glutamate standard solutions in the range from 0.5
to 10 picomol per sample. The amounts of glutamate
released in response to the depolarization of the slices
were calculated by subtracting baseline values (means of
fractions 2/4 and 9/11, respectively) from the values of
the stimulated fractions 3 and 10. These values were
used to calculate S2/S1 ratios. The statistical signifi-
cances of baclofen effects and of possible differences
between wt versus ko controls were assessed by analysis
of variance (one-way ANOVA) followed by Tukey’s test
for post hoc comparisons. Prism 3.03 (GraphPad Soft-
ware Inc., San Diego, CA, USA) was used for all the
calculations.
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Fig. 1 Effects of a GABAB antagonist and an agonist on [
3H]GABA
release in cortical slices from wt and GB1-/- mice. a In each
experiment, slices were prepared from 3 wt or 3 ko mice (males, age
10–13 weeks) and distributed into 3 different superfusion chambers
for each condition. The slices were stimulated 3 times (S1: 2 Hz,
2 min; S2 and S3: 2 Hz 0.5 min); to three chambers each containing
slices from wt or GB1-/- mice, 1 lM CGP55845 was added after
S2, from fraction 12 onwards. S1 only served to ensure comparability
with the results depicted in (b). Two identical experiments were
performed and the results pooled. Data show means ± SEM (n = 6)
of the fractional release per fraction. The S3/S2 ratios are given in the
inset. **P \ 0.01 versus control wt (two-tailed t test). b In each
experiment, slices were prepared from 3 wt or 3 ko mice (males, age
11–15 weeks) and distributed into three different superfusion cham-
bers for each condition. The slices were stimulated three times (S1:
2 Hz, 2 min; S2 and S3: 0.125 Hz, 8 min); to three chambers each
containing slices from wt or GB1-/- mice, 10 lM R(–)-baclofen
was added after S2, from fraction 12 onwards. Two identical
experiments were performed and the results pooled. Data show
means ± SEM (n = 6) of the fractional release per fraction. The S3/
S2 ratios are given in the inset. **P \ 0.01 versus control wt (two-
tailed t test)
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Results
Absence of autoreceptor-mediated regulation
of [3H]GABA release in cortical slices
of GB1-/- and GB2-/- mice
In rat brain slice preparations, GABAB antagonists increase
electrically stimulated [3H]GABA release and agonists
decrease it via the release-regulating GABAB autoreceptor
(Waldmeier and Baumann 1990). Therefore, we compared
the effects of the potent GABAB antagonist, CGP55845
(Waldmeier et al. 1993a), and of R(–)-baclofen, the active
enantiomer of the prototypical GABAB agonist, baclofen
(Baumann et al. 1990), on [3H]GABA release from cortical
slices of GB1-/- and corresponding wt mice. Based on
our previous work (Waldmeier et al. 1993a), we chose
stimulation frequencies of 2 Hz and 0.125 Hz for testing
antagonist and agonist effects, respectively. The concen-
trations of the agents in the superfusion medium (1 lM
CGP55845; 10 lM R(–)-baclofen) were previously shown
to be near-maximally to maximally effective in rat brain
slices (Waldmeier et al. 1993a).
Stimulation at 2 Hz for 2 min (S1 in Fig. 1a, b), as well
as for 0.5 min (S2 in Fig. 1a) caused a clearly more marked
release of [3H]GABA from slice preparations of GB1-/-
mice than from wt mice in the absence of any agent.
CGP55845, added after S2, caused an about fourfold
increase of [3H]GABA release at 2 Hz (0.5 min) in slices
from wt mice, similar to what was found in rat cortical
slices (Waldmeier et al. 1993a), but no change at all in
those from GB1-/- mice (Fig. 1a; for a comparison of S3/
S2 ratios see inset). Conversely, R(–)-baclofen reduced
[3H]GABA release from wt slices about fivefold, similar to
its effect on rat brain slices (Waldmeier et al. 1993a).
However, R(–)-baclofen was entirely ineffective in slices
from GB1-/- mice (Fig. 1b, see inset for S3/S2 values).
Cortical slice preparations from wt, GB1-/- and
GB2-/- mice were then stimulated consecutively with
progressively increasing frequencies to generate a fre-
quency dependence curve, in which the fractional release
of [3H]GABA per pulse (or rather, per 60 pulses in our
case) is plotted against the stimulation frequency. In a
second experiment, the same frequencies were applied in a
decreasing sequence, to eliminate any potential bias to
repetitive stimulation. It finally turned out that there was no
such bias, and the data were pooled with those of the first
experiment.
Autoreceptor-mediated regulation of transmitter release
results in a progressive reduction of the amount of trans-
mitter released per pulse with increasing stimulation
frequency (Waldmeier et al. 1993a), a pattern which is
evident in all our results with slices from wt mice (Figs. 2a,
b, 3a, b, 4a). In contrast, stimulation frequency did not
affect the amount of transmitter release per 60 pulses from
slices of GB1-/- (Fig. 2a) and GB2-/- mice (Fig. 2b),
indicating absence of autoreceptor-mediated regulation of
transmitter release. This becomes particularly clear in the
insets of Fig. 2a and b, where the values are expressed in
percent of those obtained at the lowest frequency
(0.125 Hz) for each mouse type. It should be noted that,
more so in the GB2-/- than in the GB1-/- mice, as
becomes visible at the lowest stimulation frequency, the
[3H]GABA release per (60) pulse(s) was lower than what
one might expect to obtain by just eliminating autoreceptor
regulation in wt mice, suggesting the occurrence of com-
pensatory adaptation.
Both GB1a and the GB1b subunit isoforms are involved
in autoreceptor function
Experiments identical to those above were carried out with
slice preparations from mice in which the GABAB(1) iso-
forms GB1a and GB1b were inactivated separately (i.e.
GB1a-/- and GB1b-/- mice, respectively). The results
show that in either of these mouse lines, autoreceptor-
mediated regulation of [3H]GABA release is maintained
(Figs. 3a, b). The average release per 60 pulses at each
frequency was lower in ko compared to wt mice, but the
shapes of the curves were identical, as shown in the insets
of Figs. 3a and b, where the values are expressed in percent
of those obtained at the lowest frequency (0.125 Hz) for
each mouse type.
Since the density of GB1a is higher than that of GB1b in
the striatum (Malitschek et al. 1998), one might expect the
frequency dependence curve in this area to be flatter in
GB1a-/- than in GB1b-/- mice and the reverse in hip-
pocampus, where GB1b prevail. To examine this,
frequency dependence curves were generated using striatal
and hippocampal slice preparations from corresponding ko
mice and wt controls. In striatum, the fractional release per
60 pulses was similar in all three types of mice at all fre-
quencies, but lower than in hippocampus. In the latter area,
fractional release per 60 pulses in GB1a-/- and
GB1b-/- was lower than in wt. The shapes of the fre-
quency dependence curves (insets), however, were not
different between mouse types nor areas (Fig. 4a–c).
Absence of GABAB-receptor-mediated inhibition
of the release of endogenous glutamate in cortical slices
from GB2-/-, but not from GB1a-/-
or GB1b-/- mice
The pooled data from all experiments with cortical slices
from wt mice indicate that 10 lM R(–)-baclofen inhibited
the electrically stimulated release of endogenous glutamate
by approximately 40% (S2/S1 in the control group:
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Fig. 2 Comparison of frequency dependence of [3H]GABA release
in cortical slices from wt, GB1-/- and GB2-/- mice. a Slices were
prepared from two male wt or two male GB1-/- (age 13 weeks)
mice and distributed into six different superfusion chambers for each
group. The slices were stimulated five times with the same number of
pulses (60), but progressively increasing frequency. A second
experiment with slice preparations from two male wt mice and two
male GB1-/- mice (age 15 weeks) was performed in which the
frequency sequence was reversed (degressive). The results were
pooled. Data represent the means ± SEM (n = 12) of the stimulated
fractional release at the different frequencies (S1[0.125 Hz] – S5[2 Hz]).
The inset shows the same data expressed as percent of S1 of the
respective groups. b Slices were prepared from a male and a female
wt mouse (age 11 weeks) or a male and a female GB2-/- mouse
(age 10 weeks) and distributed into six different superfusion cham-
bers for each group (wt or ko). The slices were stimulated five times
with the same number of pulses (60), but progressively increasing
frequency. A second experiment with slice preparations from a male
and a female wt mouse (age 16 weeks) or a male and a female
GB2-/- mouse (age 16 weeks) was performed in which the
frequency sequence was reversed (degressive). The results were
pooled. Data represent the means ± SEM (n = 12) of the stimulated
fractional release at the different frequencies (S1[0.125 Hz] – S5[2 Hz]).
The inset shows the same data expressed as percent of S1 of the
respective groups. + significantly lower (P \ 0.01) than the corre-
sponding wt group; * significantly different from the wt value at the
lowest stimulation frequency (S1) (P \ 0.01, ANOVA/Dunnett’s test)
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1.19 ± 0.04 [n = 29], with baclofen: 0.73 ± 0.03,
n = 28, P \ 0.001). The individual results obtained with
slices from wt mice used as a reference for comparison
with slices from ko animals are shown on the respective
graphs in Fig. 5. The inhibitory effect of baclofen on glu-
tamate release was completely abolished in cortical slices
from ko mice lacking the GB2 receptor subunit (S2/S1
without baclofen: 1.13 ± 0.1, with baclofen: 1.28 ± 0.13,
n = 5 per group) (Fig. 5a). On the other hand, in slices
from GB1a-/- mice, the inhibitory effect of 10 lM R(–)-
baclofen was reduced, but not abolished, when compared
to wt controls (Fig. 5b). In fact, the S2/S1 ratios in the slices
from the ko animals were 1.05 ± 0.04 (n = 12) in the
absence, and 0.9 ± 0.04 (n = 10) in the presence of
10 lM R(–)-baclofen, corresponding to an inhibition of
14%. A different situation was found in tissue from
GB1b-/- mice. In these cortical slices, R(–)-baclofen was
still able to produce essentially the same degree of inhi-
bition of glutamate release as in tissue from wt animals
(S2/S1 = 1.09 ± 0.05, n = 12, in the control group;
S2/S1 = 0.74 ± 0.05, n = 9, with baclofen, 32% inhibi-
tion, P \ 0.001).
Discussion
The release of [3H]GABA from GABAergic nerve termi-
nals is normally under an inhibitory control by the synaptic
concentration of GABA, mediated by autoreceptors of the
GABAB type. This can be conveniently demonstrated by
measuring [3H]GABA overflow (in the following termed
release) from preloaded brain slices, or the release of
endogenous GABA, evoked by electrical field stimulation.
The presence of a GABA uptake inhibitor facilitates
the measurements, but does not qualitatively affect the
results. Characteristically, the electrically evoked release of
[3H]GABA per impulse progressively decreases with
increasing stimulation frequency in the range of approxi-
mately 0.05–2 Hz, reflecting activation of the autoreceptor
by endogenously released GABA (Waldmeier et al. 1994).
This can be used for assessing the effects of GABAB
agonists, which reduce, and of antagonists, which enhance
[3H]GABA release at a given stimulation frequency. Most
of the previous work on autoreceptor-mediated regulation
of GABA release has been done using rat brain slices, but
our control data shown here demonstrate that results
obtained with brain slices from wt mice are very similar.
Thus, the prototypical GABAB antagonist CGP55845
increased and the prototypical GABAB agonist (–)-baclo-
fen reduced the release of [3H]GABA from cortical slices
of wt Balb/c mice in much the same way as previously
shown in rat cortical slices (Waldmeier et al. 1993a, 1994).
The effects of both compounds were eliminated in mice
lacking both subtypes of ligand-binding GB1 subunits
(Fig. 1). Moreover, in the absence of any drug, [3H]GABA
release evoked by 2 Hz was much higher in GB1-/- mice
(Fig. 1). Both this finding and the absence of drug effects
are most likely due to absence of inhibitory autoreceptor
control. This was confirmed by comparing frequency
curves, i.e. the fractional release of [3H]GABA per a given
number of pulses plotted against the stimulation frequency:
while wt mice showed frequency curves comparable to
those reported in rats, no dependence of this parameter on
the stimulation frequency was observed in GB1-/- mice.
This result is an unmistakable sign of absence of autore-
ceptor regulation. Eliminating the GB2 subunit of the
heterodimeric GABAB receptor complex, responsible for
effector coupling, also causes a complete loss of frequency
dependence of [3H]GABA release, indicating that this
subunit is just as essential for autoreceptor function as the
GB1 subunits.
Corresponding experiments with cortical, hippocampal
and striatal slices from mice in which expression of the
GB1a or GB1b subunits, respectively, was disabled, sug-
gested that both subtypes can convey autoreceptor function
to their heterodimeric receptor complex with GB2. Frac-
tional release per 60 pulses was lower in slices from both
ko types than in wt mice at all stimulation frequencies
examined, making the frequency curves look shallower.
However, on normalization to the values at 0.125 Hz
(insets in Figs. 3, 4), wt and ko frequency curves were
identical, indicating little if any difference in autoreceptor
function of the corresponding heterodimeric receptor
complexes. This is also suggested by the fact that fre-
quency curves obtained with striatal and hippocampal
slices of GB1a-/- and GB1b-/- mice showed the same
pattern, i.e. shallower curves in striatum. If there were a
difference in autoreceptor function of the corresponding
heterodimeric receptor complexes, one might have expec-
ted a change in this pattern, since GB1a subunits prevail in
the striatum and GB1b subunits in the hippocampus
(Malitschek et al. 1998).
Of note, fractional release per 60 pulses was also lower
at 0.125 Hz in both GB1a-/- and GB1b-/- mice. A
downregulation of GABA release by unknown compensa-
tory mechanisms as a reaction to the absence of these
subunits might be responsible for this phenomenon.
GABAB receptor-mediated inhibition of glutamate
release, as measured by the ability of R(–)-baclofen to
reduce electrically evoked release of endogenous glutamate
from cortical slices, was also completely abolished in
GB2-/- mice, whereas this agent caused a reduction in wt
mice similar in extent as previously reported for rats
(Waldmeier et al. 1993b). Interestingly, a difference in the
ability of R(–)-baclofen to reduce glutamate release
emerged in the experiments on GB1a-/- and GB1b-/-
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Fig. 3 Comparison of frequency dependence of [3H]GABA release
in cortical slices from wt, GB1a-/-, and GB1b-/- mice. a Slices
were prepared from three female wt (age 10 weeks) or three female
GB1a-/- (age 24 weeks) mice and distributed into six different
superfusion chambers for each group (wt or ko). The slices were
stimulated five times with the same number of pulses (60), but
progressively increasing frequency. A second experiment with slice
preparations from a male and a female wt mouse (age 41 and
22 weeks, respectively) or a male and a female GB1a-/- mouse (age
41 and 22 weeks, respectively) was performed in which the frequency
sequence was reversed (degressive). The results were pooled. Data
represent the means ± SEM (n = 12) of the stimulated fractional
release at the different frequencies (S1[0.125 Hz] – S5[2 Hz]). The inset
shows the same data expressed as percent of S1 of the respective
groups. b Slices were prepared from two male wt mice (age 14 and
41 weeks) and two male GB1b-/- mice (age 11 and 21 weeks) and
distributed into six different superfusion chambers for each group.
The slices were stimulated five times with the same number of pulses
(60), but progressively increasing frequency. A second experiment
with slice preparations from two male wt mice (age 14) and two male
GB1b-/- mice (age 14 weeks) was performed in which the
frequency sequence was reversed (degressive). The results were
pooled. Data represent the means ± SEM (n = 12) of the stimulated
fractional release at the different frequencies (S1[0.125 Hz] – S5[2 Hz]).
The inset shows the same data expressed as percent of S1 of the
respective groups. +/++ significantly lower (P \ 0.05/P \ 0.01)
than the corresponding wt group; */** significantly different from the
corresponding S1 value (P \ 0.05/P \ 0.01, ANOVA/Dunnett’s test)
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mice.. In GB1a-/- mice, the inhibitory effect of R(–)-
baclofen was markedly reduced, but not completely abol-
ished as compared to wt mice, whereas in GB1b-/- mice,
it was essentially unaltered. The latter result suggests that
GABAB heteroreceptors involved in the regulation of
glutamate release are predominantly, but not exclusively,
composed of GABAB(1a/2) heterodimers.
Three very recent electrophysiological studies, using the
same ko animals as the ones which served for our work,
have addressed the role of the two receptor isoforms in pre-
and postsynaptic GABAB receptor functions. Pe´rez-Garci
et al. (2006) have demonstrated that postsynaptic inhibition
of dendritic Ca2+ spikes in neocortical pyramidal neurons
is mediated by GB1b, whereas in their case, somewhat at
variance with our findings, presynaptic inhibition of GABA
release was mediated by GB1a. At the same time, Vigot
et al. (2006), by means of whole cell patch clamp elec-
trophysiology, investigated the presence of functional
GABAB heteroreceptors on excitatory terminals and auto-
receptors on GABAergic terminals, in slices from the
hippocampus of GB1-/-, GB1a-/-, and GB1b-/-
mice. Autoreceptor activation by baclofen in either
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Fig. 4 Comparison of
frequency dependence of
[3H]GABA release in striatal
versus hippocampal slices from
wt, GB1a-/- and GB1b-/-
mice. Striatal and hippocampal
slices were prepared from five
male and five female wt mice
(age 17–41 weeks) (a), five
male and five female GB1a-/-
mice (age 13–48 weeks) (b), or
five male and five female
GB1b-/- mice (age 49–
56 weeks) (c) and distributed
into six different superfusion
chambers for each group. The
slices were stimulated five times
with the same number of pulses
(60), but progressively
increasing frequency. Data
represent the means ± SEM
(n = 6) of the stimulated
fractional release at the different
frequencies (S1[0.125 Hz] –
S5[2 Hz]). The inset shows the
same data expressed as percent
of S1 of the respective groups.
*/** significantly different from
the corresponding S1 value
(P \ 0.05/P \ 0.01, ANOVA/
Dunnett’s test)
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GB1a-/-, and GB1b-/- mice was similar to wt mice,
suggesting that both isoforms can substitute for each other
to inhibit GABA release from GABAergic terminals. This
corresponds exactly to the results of our direct measure-
ments of GABA release in cortical, hippocampal and
striatal slices. With respect to functional heteroreceptors on
excitatory terminals, Vigot et al. (2006) found a much
smaller inhibition of excitatory synaptic transmission by
baclofen in GB1a-/-, mice than in wt or GB1b-/-, mice,
suggesting a predominant role of GB1a. Again, the results
of our measurements of the release of endogenous gluta-
mate in cortical slices lead to exactly the same conclusion.
Also, Shaban et al. (2006) have demonstrated that GB1a
containing receptors are the key heteroreceptors mediating
presynaptic inhibition at glutamatergic cortical and tha-
lamic afferents in the amygdala, whereas GABAB
autoreceptor mediated presynaptic inhibition at GABAer-
gic terminals was not different in GB1a-/- and GB1b-/-
mice when compared to wildtypes.
To our knowledge, this is the first study using release
experiments to elucidate the role of 1a and 1b isoforms in
presynaptic GABAB receptor function. Whereas results
from electrophysiological experiments usually reflect
events occurring at the level of individual cells, biochem-
ical observations such as the ones described here integrate
over larger brain areas and therefore allow more general-
ized conclusions. Therefore, we believe that our work
nicely confirms and extends the conclusions drawn from
the electrophysiological studies mentioned above.
In summary, our study suggests that GB1a and GB1b
differentially contribute to GABAB auto- and heterore-
ceptor functions. There is as yet no evidence for
pharmacological differences between receptor complexes
containing the GB1a and GB1b isoforms (Kaupmann et al.
1998a, b; Malitschek et al. 1998). This is not surprising as
the two isoforms do not differ in their ligand binding
domains to which all of the currently available competitive
agonists and antagonists bind (Bettler et al. 2004). The
identification of GB1a as a possible molecular target to
selectively interfere with GABAB heteroreceptor function
suggests the further search for pharmacological means to
selectively target GB1 isoforms may be warranted.
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